As Chief Scientific Officer, Greg Babcock is responsible for strategic leadership of all areas of research for the company. Greg joined Visterra in 2013 and has 25 years of experience researching and developing monoclonal antibodies for a variety of disease indications. Previously, Greg served as the Deputy Director of MassBiologics, building and leading the research… READ MORE>>

As Vice President, Pharmaceutical Sciences and Technology, Jean Bender is accountable for leading all CMC activities for Visterra’s product pipeline. Prior to Visterra, Jean led the BioProcess Engineering department at Medimmune LLC where she was responsible for process development engineering, scale-up and transfer of drug substance processes. Previously she held roles of increasing responsibility within… READ MORE>>

As Chief Financial Officer, Todd Curtis oversees all Visterra’s finance functions, including finance, accounting, planning and analysis, and tax functions. Todd is also responsible for enterprise systems and facilities. Todd joined Visterra in 2015 and has more than 15 years of finance and operations leadership experience within the biotechnology and software sectors and an additional… READ MORE>>

As Chief Operating Officer, Chris is responsible for program management, business planning, alliance and affiliate collaboration, IP, finance, HR, legal and compliance activities. Prior to joining Visterra, Chris served in senior positions at Momenta Pharmaceuticals, Ironwood Pharmaceuticals and Genzyme Corporation. Chris began his career as a corporate attorney with the Boston law firm of Palmer… READ MORE>>

As Chief Medical Officer, Asher Schachter oversees early phase clinical research and development for Visterra’s clinical biologic assets, spanning a broad therapeutic spectrum including nephrology, rheumatology/autoimmune diseases, transplant immunology and neurodegenerative diseases, aiming to de-risk assets through clinical PoC and transition to late phase development in cooperation with Otsuka partners. Asher joined Visterra in 2020… READ MORE>>

As President and Chief Executive Officer, Zachary Shriver oversees all aspects of Visterra and its interactions with Otsuka, including research & development, accounting & finance, legal, pharmaceutical sciences & technology, operations, business development and strategy. Zachary joined Visterra in 2009 as Vice President of Research and has 25 years of experience in the biotechnology industry…. READ MORE>>

As Vice President, Nonclinical Development, Susan Sloan is responsible for IND-enabling and early-phase development activities that span preclinical, bioanalytical, and clinical pharmacology to transition programs from research to the clinic, and support programs in early-phase clinical development. Susan also oversees the Quality function. Susan joined Visterra in 2013 and has 20 years of biologics drug… READ MORE>>

As Vice President, Research, Karthik Viswanathan provides leadership to several discovery programs and is responsible for Visterra’s computational and protein engineering platforms. Karthik joined Visterra in 2009 as its founding scientist and helped establish the Hierotope™ platform that has led to discovery and development of several therapeutics. He is an inventor of multiple drugs in… READ MORE>>

As Vice President, Head of Clinical Operations,  Jill Yarbrough has responsibility and oversight of our clinical programs and outsourcing strategy. Jill joined Visterra in 2019 and has over 30 years of drug and diagnostic development experience.  Jill has dedicated her career to transforming clinical trials.  She has acquired her experience via various positions within clinical… READ MORE>>